8-K: Current report
3: Initial statement of beneficial ownership of securities-Director Lee Phil Geon
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
8-K: Current report
10-Q: Quarterly report
8-K: Current report
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
8-K: Current report
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
8-K: Current report
DEF 14A: Definitive information statements
8-K: Current report
10-K: Annual report
PRE 14A: Preliminary proxy statements relating to merger or acquisition
BELLEVUE LIFE SCIENCES ACQ CORP COM USD0.0001 (SUB RIGHTS) | 8-K: Current report
BELLEVUE LIFE SCIENCES ACQ CORP COM USD0.0001 (SUB RIGHTS) | NT 10-K: Others
BELLEVUE LIFE SCIENCES ACQ CORP COM USD0.0001 (SUB RIGHTS) | 8-K: Current report
BELLEVUE LIFE SCIENCES ACQ CORP COM USD0.0001 (SUB RIGHTS) | 8-K: Current report
BELLEVUE LIFE SCIENCES ACQ CORP COM USD0.0001 (SUB RIGHTS) | 8-K: Current report
BELLEVUE LIFE SCIENCES ACQ CORP COM USD0.0001 (SUB RIGHTS) | SC 13G: Statement of acquisition of beneficial ownership by individuals-Bellevue Global Life Science Investors, LLC(36.2%),Bellevue Capital Management LLC(36.2%), etc.
No Data